No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CERS240517C1000
- 0.90
- 0.000.00%
15min DelayTrading Apr 8 14:43 ET
0.00High0.00Low
0.00Open0.90Pre Close0 Volume13 Open Interest1.00Strike Price0.00Turnover0.00%IV-0.54%PremiumMay 17, 2024Expiry Date0.84Intrinsic Value100Multiplier9DDays to Expiry0.07Time Value100Contract SizeAmericanOptions Type--Delta--Gamma2.22Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Cerus's Strong Q1 Growth and Promising INTERCEPT Technology Drive Buy Rating
Cerus First Quarter 2024 Earnings: EPS Misses Expectations
Cerus Is Maintained at Overweight by Cantor Fitzgerald
Cerus Is Maintained at Overweight by Cantor Fitzgerald
Cerus Price Target Raised to $4.00/Share From $3.00 by Cantor Fitzgerald
Cerus Price Target Raised to $4.00/Share From $3.00 by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Cerus, Raises Price Target to $4
Cerus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 130.55% Cantor Fitzgerald $3 → $4 Maintains Overweight 04/12/2024 188.18% Craig-Hallum → $5 Ini
Comments
$Cerus(CERS.US$ Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
1
$Cerus(CERS.US$ Cerus Announces Positive Results For Phase 3 Trial Of Intercept Blood System
$Cerus(CERS.US$ That gap at 2.11 almost filled!
6
Read more